Advertisement Ranbaxy launches pravastatin sodium tablets in the US - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Ranbaxy launches pravastatin sodium tablets in the US

Ranbaxy Pharmaceuticals has officially launched pravastatin sodium 80mg tablets, a generic version of Bristol-Myers Squibb's Pravachol, in the US.

Being the first to file, Ranbaxy will enjoy 180-day exclusivity for pravastatin 80mg. According to the company, the annual sales for the heart drug are $209 million.

Pravastatin is indicated in the treatment of primary prevention of several types of coronary diseases, and is the therapeutic equivalent to the reference listed drug Pravachol, which is marketed by Bristol-Myers Squibb.